Clinical Trials MELD-ATG

ATG, given once in a two days infusion regimen, is a drug recently shown to be able to keep the balance between attacking and regulating cells within the immune system, and thereby helping to preserve insulin secretion.

The drug ATG (Anti Thymocyte Globulin) provided by our partner Sanofi, will be tested over 12 months in adolescents to adults (5-25 years for now, soon to be followed by 5 to 25 years, n=114). ATG, given once in a two days infusion regimen, is a drug recently shown to be able to keep the balance between attacking and regulating cells within the immune system, and thereby helping to preserve insulin secretion. Defining the minimal effective dose of ATG treatment is one aim of the study.

In this movie, the trial specific information starts at minute 3.

For more Information

Please download the PDF below:

Other Innodia Trials:

How to Participate:

Select country:

Germany
Denmark
Great Britain
Italy
Austria
Sweden
Belgium
  • Germany

    Germany - HKA Hannover

  • Denmark

    Denmark

  • Great Britain

    UK - Cambridge

  • Italy

    Italy

  • Great Britain

    Slovenia - UMC Ljubljana

  • Austria - MUG

    Austria - MU Graz

  • Austria - MUG

    Austria - MU Vienna

  • Belgium

    Belgium - UZ Leuven

  • Belgium

    Belgium - UZ Antwerpen

  • Belgium

    Belgium - UZ Brussels

  • Belgium

    Belgium - UZ Sint-Lukas

  • Belgium

    Belgium - ULB Brussel

Is your country not available?
Send us a mail so we can contact you when the trial starts close to you!